The discoveries of EGFR mutations and ALK rearrangements as actionable oncogenic
drivers in non-small-cell lung cancer (NSCLC) has propelled a biomarker-directed treatment …

Lung cancer accounts for a quarter of all cancer deaths. Non-small cell lung cancer
(NSCLC) is currently segregated by the presence of actionable driver oncogenes. This …

Precision oncology is now the evidence-based standard of care for the management of
many advanced non-small cell lung cancers (NSCLCs). Expert consensus has defined …

The first-generation epidermal growth factor receptor tyrosine kinase inhibitors erlotinib and
gefitinib have been incorporated into treatment paradigms for patients with advanced non …

EGFR is a tyrosine kinase that participates in the regulation of cellular homeostasis.
Following ligand binding, EGFR stimulates downstream cell signaling cascades that …

The development of targeted therapies has revolutionized the treatment of cancer patients.
The identification of “druggable” oncogenic kinases and the creation of small-molecule …

EGFR-activating mutations are observed in approximately 15% to 20% of patients with non–
small cell lung cancer. Tyrosine kinase inhibitors have provided an illustrative example of …

The discovery that mutations in the EGFR gene are detected in up to 50% of lung
adenocarcinoma patients, along with the development of highly efficacious epidermal …

Non-small cell lung cancers (NSCLCs) are heterogeneous cancers. In 2004, the
identification of epidermal growth factor receptor (EGFR) somatic mutations provided the first …

Purpose: To identify novel mechanisms of resistance to third-generation EGFR inhibitors in
patients with lung adenocarcinoma that progressed under therapy with either AZD9291 or …